Overview

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure [msSBP] ≥ 140 mmHg and < 180 mmHg and/or mean sitting Diastolic Blood Pressure [msDBP] ≥ 90 and <110 mmHg).
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Amlodipine
Hydrochlorothiazide